22.750
+1.250
+(5.81%)
As of 9:57:47 AM GMT+8. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
630,201
630,201
837,999
426,409
356,128
Cost of Revenue
348,884
348,884
384,447
311,103
258,234
Gross Profit
281,317
281,317
453,552
115,306
97,894
Operating Expense
321,927
321,927
432,043
521,565
425,893
Operating Income
-40,610
-40,610
21,509
-406,259
-327,999
Net Non Operating Interest Income Expense
37,208
37,208
35,386
8,947
1,484
Pretax Income
-1,107
-1,107
58,308
-410,422
-215,740
Tax Provision
7,192
7,192
4,509
-283
11,918
Net Income Common Stockholders
37,729
37,729
100,780
-360,835
-194,648
Diluted NI Available to Com Stockholders
37,729
37,729
100,780
-360,835
-194,648
Basic EPS
0.04
--
0.12
-0.43
-0.25
Diluted EPS
0.04
--
0.12
-0.43
-0.25
Basic Average Shares
855,351.683
--
849,654.296
847,143.540
792,684.524
Diluted Average Shares
872,829.129
--
869,196.348
847,143.540
792,684.524
Total Expenses
670,811
670,811
816,490
832,668
684,127
Net Income from Continuing & Discontinued Operation
37,729
37,729
100,780
-360,835
-194,648
Normalized Income
41,332
41,332
106,100.111
-358,736.088
-276,219.500
Interest Income
40,080
40,080
36,145
9,599
2,076
Interest Expense
2,872
2,872
759
652
592
Net Interest Income
37,208
37,208
35,386
8,947
1,484
EBIT
1,765
1,765
59,067
-409,770
-215,148
EBITDA
14,106
14,106
67,274
-401,106
-207,958
Reconciled Cost of Revenue
348,884
348,884
384,447
311,103
258,234
Reconciled Depreciation
12,341
12,341
8,207
8,664
7,190
Net Income from Continuing Operation Net Minority Interest
37,729
37,729
100,780
-360,835
-194,648
Total Unusual Items Excluding Goodwill
-4,804
-4,804
-5,766
-2,452
108,762
Total Unusual Items
-4,804
-4,804
-5,766
-2,452
108,762
Normalized EBITDA
18,910
18,910
73,040
-398,654
-316,720
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-1,201
-1,201
-445.889
-353.088
27,190.500
12/31/2021 - 6/30/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
3320.HK China Resources Pharmaceutical Group Limited
4.980
+1.43%
2633.HK Jacobson Pharma Corporation Limited
1.280
+2.40%
0460.HK SIHUAN PHARM
0.640
+1.59%
KABRADG.BO Kabra Drugs Limited
11.08
0.00%
002923.SZ Zhuhai Rundu Pharmaceutical Co., Ltd.
13.91
-0.78%
002900.SZ Harbin Medisan Pharmaceutical Co., Ltd.
14.21
-0.56%
GODAVARI.BO Godavari Drugs Limited
93.00
+1.34%
SHILPAMED.BO Shilpa Medicare Limited
634.05
+4.04%
82P.BE Pacira BioSciences Inc
21.20
-9.40%
EVT.VI Evotec SE
5.32
-1.66%